|
Dear Christine
Unfortunately, I knew quite awhile ago that I would not be able to join you in San Antonio (but I plan on meeting you somewhere, sometime - maybe Atlanta). But, I would be very interested in what the HERA trial team says about the second year of Herceptin as an adjuvant and if there are any indications it is better than one year (not necessarily extremely better but if one year reduces the chance of recurrence by 46% and two years is better than 52% that would be great).
Warm regards
Becky
|